Escitalopram ?s effectiveness on treatment of depressive disorder and improvement of quality of life in patients who are undergone coronary artery bypass graft surgery

The study of of Escitalopram ?s effectiveness on treatment of mild to moderate depressive disorder and improvement of quality of life in patients who are undergone coronary artery bypass graft surgery (CABG) – A randomized double blind placebo controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140126016374N2

Enrollment

Registered

2020-11-22

Start date

2020-11-21

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression Disorder. Other depressive episodes

Interventions

Intervention 1: Intervention group: take escitalopram 10 mg? once daily ? oral ? pruduct by Abidi company ?For 8 weeks. Intervention 2: Control group: take placebo tablet ? Produced by Abaidi Company?

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: coronary artery bypass graft surgery Age >18 (18-75) patient with beck depression inventory score 10-20

Exclusion criteria

Exclusion criteria: Previous history of intolerance to serotonin reuptake inhibitor antidepressants Psychosis or dementia or mental retardation disorder in the patient Severe liver disease High risk of postoperative cardiac complications such as bleeding Patients participating in other trials History of bipolar disorder Patients who have been treated with escitalopram or an antidepressant during the previous month Recent abuse of alcohol and substances Pregnancy and lactation

Design outcomes

Primary

Measure	Time frame
Degree of Depression. Timepoint: Beginning of the study (before the intervention)? Week 4? Week 8 (after treatment)?. Method of measurement: Beck Depression Inventory (BDI-II).;Quality of life. Timepoint: Beginning of the study (before the intervention)? Week 4 ? Week 8 (after treatment)?. Method of measurement: Quality of Life questionnaire ? 36-Item Short Form (SF-36).	—

Secondary

Measure	Time frame
Drug complication. Timepoint: 2 and 4 weeks after taking the drug. Method of measurement: Checklist of drug side effects.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Asadian Kuhestani

University of social welfare and rehabilitation sciences

f.asadian1392@gmail.com+98 21 3340 1604

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 6, 2026